Free Trial

Aspira Women's Health Q1 2024 Earnings Report

Aspira Women's Health logo
$0.79 +0.04 (+5.00%)
(As of 09:09 AM ET)

Aspira Women's Health EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$10.94

Aspira Women's Health Revenue Results

Actual Revenue
$2.15 million
Expected Revenue
$2.10 million
Beat/Miss
Beat by +$50.00 thousand
YoY Revenue Growth
N/A

Aspira Women's Health Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available 

Aspira Women's Health Earnings Headlines

Healthcare Takes A Big Step Forward With The Help of A.I.
To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.
Aspira Women's Health (NASDAQ:AWH) Now Covered by StockNews.com
See More Aspira Women's Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aspira Women's Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspira Women's Health and other key companies, straight to your email.

About Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

View Aspira Women's Health Profile

More Earnings Resources from MarketBeat

Upcoming Earnings